Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises PEQ Invest in connection with the acquisition of Cookin Food Sweden AB (”Cookin”)
Mandate

Vinge advises PEQ Invest in connection with the acquisition of Cookin Food Sweden AB (”Cookin”)

October 15, 2024 M&A Real Estate and Construction Banking and Finance Employment and Benefits Corporate Commercial Data protection and processing of personal data

Founded in 2011 by experienced chefs, bakers and restaurant owners, Cookin has a strong presence in the airline and retail sectors and offers high quality ready-made meals that are customised to the customers’ needs.

Vinge’s team consisted mainly of Jonas Johansson, Philip Moré and Alex Forsberg (M&A), Kristoffer Larson (Real Estate), Arvid Weimers and August Ahlin (Banking and finance), Emil Lindwall and Agnes Källström (Employment), Mario Saad and Ian Linde (Corporate Commercial), Jolene Reimerson and Sara Hedgren (GDPR) and Cecilia Loctander (Transaction Support Coordinator)

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026